Aldevron is now offering its pALD-HELP, an off-the-shelf product supporting AAV viral vector manufacturing, in its proprietary GMP-Source® (GMP-S) quality level. The plasmid is royalty-free for all applications in support of pre-clinical activities through clinical development.

The addition of this widely used plasmid expands Aldevron’s suite of ready-to-use and royalty-free constructs in support of making AAV via triple transfection, including its rep/cap plasmids 2, 5 and 6. The pALD-AAV6 plasmid is also available at the GMP-Source quality level.

“We launched this Ad helper plasmid in Research Grade as an inventory product earlier this fall and it was very well received,” said Michelle Berg, President, GMP Nucleic Acids for Aldevron. “Offering pALD-HELP in our GMP-Source quality level is another way we can support our clients in their efforts to get potential therapies to their patients sooner. Aldevron continuously looks for ways to improve our service to clients and expanding our portfolio of standardized products across quality levels ensures they have the quality products they need, when they need them.”

Aldevron has more than 23 years of experience manufacturing high-quality custom products that are used by companies around the world, along with a catalog of products that provide a consistent, reliable option to help clients meet deadlines. In addition to the AAV construct suite, Aldevron’s inventory product lines also include lentivirus plasmids, IVT enzymes, and a variety of CRISPR nucleases.

Aldevron announced today the immediate availability of rep/cap plasmids pALD-AAV2, AAV5 and AAV6 to support AAV viral vector manufacturing. All three rep/cap plasmids are immediately available at Research Grade. Additionally, pALD-AAV6 is immediately available at the GMP-Source® quality level, while pALD-AAV2 and pALD-AAV5 will be made available based on market demand. The plasmids are royalty free for all applications in support of pre-clinical activities through clinical development and commercial production.

Aldevron is excited to announce our partnership with MEEI to support its manufacturing of an experimental vaccine for clinical studies for its AAVCOVID vaccine program.

Aldevron is scheduled to present, exhibit and conduct one-on-one meetings at the Biotechnology Innovation Organization’s (BIO) International Convention, June 3 – 6, 2019, in Philadelphia. Aldevron’s James Brown, VP Corporate Development, is speaking on standardized helper plasmids for viral vector production.

Novel Packaging and Expression Plasmids Promise to Reduce Gene Therapy Manufacturing Costs and Delivery Times

Miami, FL - Aldevron announced from Phacilitate Leaders World in Miami the immediate availability of standardized plasmids for lentiviral production through a license agreement with Oxford Genetics.